(352) Ionic liquid-based nanoemulsion to improve sorafenib oral absorption & repurposing it in AML therapy
Introduction: Acute myeloid leukemia (AML) is a hematological malignancy with FLT3 mutations being the most common, driving aggressive progression [1]. Sorafenib (SRF), an FDA-approved drug repurposed for AML with FLT3 mutations faces challenges due to poor solubility & low oral bioavailability (38-49%) [2, 3]. Ionic liquids (ILs) offer excellent solvation properties. Previously we developed metformin-docusate (MD), an amphiphilic IL with high lipid solubility [4]. Here, we created a self-nanoemulsifying system (SNES) of MD with solubilized SRF to improve its bioavailability & therapeutic potential for AML.
Learning Objectives:
Explore the translational implications of ionic liquid based drug delivery.
Investigate the use of amphiphilic IL in nanoemulsion for oral delivery of hydrophobic drug.
Demonstrate the potential of amphiphilic IL to improve PK of SRF and repurposing for AML therapy.
Upendar Golla – Researcher, Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; Pratik Patel – Post-doctoral fellow, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, Hilo Hawaii 96720, USA; Roopal Bhat – Research associate, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, Hilo Hawaii 96720, USA; Jaishree Mali – Research associate, Department of Pharmacology and Toxicology, University of Arizona; Sudipta Mallick – Post-doctoral fellow, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, Hilo Hawaii 96720, USA; Arati Sharma – Professor, Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; Abhijit Date – Assistant professor, Department of Pharmacology and Toxicology, R. K. Coit College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
